ERBB2 and ovarian carcinoma: Several other trials where vaccines were tested include: (i) A phase I study (NCT01376505) on a vaccine composed of two HER2 peptides—MVF-HER-2 and MVF-HER-2, tested in various metastatic tumours, including ovarian cancer, and (ii) A study on ID-LV305 vaccine, comprising of lentiviral vector aiming dendritic cells, and consisting sequences encoding the NY-ESO-1 antigen (NCT02122861) [98].